| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 8, 2021
South San Francisco, CA, September 8, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Aug 10, 2021Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-
South San Francisco, CA, August 10, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Jul 28, 2021
South San Francisco, CA, July 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine...
-
Jun 22, 2021
June 22, 2021 South San Francisco, CA, June 22, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal...
-
Jun 16, 2021- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -
South San Francisco, CA, June 16, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...